Advertisement


Bharat Biotech
India  /  Published 16.08.22

Nasal Covid vaccine finishes clinical trials

A candidate intranasal vaccine against Covid-19, jointly developed by US scientists and India’s Bharat Biotech, has completed clinical trials as both a standalone vaccine and a booster, the vacc...
By G.S. Mudur in New Delhi

India  /  Published 15.08.22

Intranasal vaccine proven safe: Bharat Biotech

Bharat Biotech International Limited (BBIL) on Monday said its COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials pha...
By PTI in Hyderabad

India  /  Published 17.06.22

'Covaxin safe for 2-18 years age'

Bharat Biotech International Limited (BBIL) on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III st...
By Our Bureau, PTI in Hyderabad

India  /  Published 26.05.22

Germany approves Covaxin

German Ambassador to India and Bhutan, Walter J Lindner on Thursday said the government of the European nation will start recognizing Bharat Biotech's COVID-19 vaccine for travel purpose there fro...
By Our Bureau, PTI in Hyderabad

India  /  Published 24.05.22

FDA lifts hold on Covaxin in US

The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued...
By Our Bureau, PTI in Hyderabad

Advertisement

India  /  Published 04.05.22

Bharat Biotech seeks DCGI nod

Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI. Pr...
By Our Bureau, PTI in New Delhi

India  /  Published 26.04.22

Covaxin nod for kids aged 6-12

India's drug regulator has granted emergency use authorisation for Biological E's COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech's Covaxin for children in the...
By Our Bureau, Agencies in New Delhi

Opinion  /  Published 14.04.22

Letters to the Editor

Sensory pleasure Sir — Sigmund Freud used the term, osphresiolagnia, to describe pleasure derived from smells. None will understand this better than a book lover; the enticing scent of a book, ...

India  /  Published 10.04.22

Booster jab cost cut, cry on equity

Covaxin and Covishield boosters will be available to private hospitals at Rs 225 per dose under revised and lowered prices announced by vaccine makers on Saturday, a day before the booster campaign op...
By G.S. Mudur in New Delhi

India  /  Published 03.04.22

Bharat Biotech hits back at WHO

India's Covid-vaccine manufacturing firm, Bharat Biotech on Sunday issued a clarification that there is " no impact on efficacy and safety of the Covid-19 vaccine Covaxin", after the&nbs...
By Our Bureau, Agencies in New Delhi


Advertisement

Download our latest App

to get update on the go...

Advertisement

Advertisement
 
Copyright © 2020 The Telegraph. All rights reserved.